Close

Athersys (ATHX) Receives FDA Okay Under a SPA for Phase 3 Study of MultiStem

September 28, 2016 6:31 AM EDT Send to a Friend
Athersys, Inc. (NASDAQ: ATHX) announced today that it has received agreement from the U.S. Food and Drug Administration (FDA) under ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login